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Abstract
Pulmonary involvement in Behçet’s disease (BD) is uncommon; however, it is potentially fatal due to the risk of massive
haemoptysis.Wedescribe the case of a 36-year-oldmale presentingwith a 2-monthhistoryofworsening dyspnoea,weight loss,
haemoptysis, oral ulceration, erythema nodosum and superficial thrombophlebitis. He was diagnosed with pulmonary
vasculitis secondary to BD; however, his symptoms were refractory to initial treatment with cyclophosphamide, azathioprine
and prednisolone. We therefore trialled infliximab alongside methotrexate, which led to a remarkable improvement in his
condition, enabling eventual discontinuation of prednisolone. Whilst not being one of the treatments currently recommended
for managing pulmonary involvement in BD, infliximab has previously been successfully used in cases refractory to
conventional therapy. We used the 6-min walk test (distance covered and lowest oxygen saturations) to monitor his progress,
which correlated with his symptoms. This may represent a useful adjunct in monitoring the activity of pulmonary vasculitis.
INTRODUCTION
Pulmonary involvement in Behçet’s disease (BD) has a preva-
lence of 1–7.7% [1]. Aneurysms are the commonest form of pul-
monary involvement; other features include arterial and venous
thrombosis and pulmonary infarction [1, 2]. Mortality rates of up
to 30% are reported due to the risk of massive haemoptysis [1].
Pulmonary disease does not feature in either the Internation-
al Study Group Criteria [3] or the International Criteria for Beh-
çet’s Disease (ICBD) [4] for diagnosing BD; the ICBD group only
found a 2.4% prevalence of pleuro-pulmonary manifestations
when studying 1278 subjects [4]. Nevertheless, given the high
rate of mortality associated with it, it is important to be vigilant
for signs of pulmonary vasculitis in BD and to initiate appropriate
treatment.
We present a case of Behçet’s pulmonary vasculitis refractory
to conventional immunosuppressants that was subsequently
treated with infliximab. Disease activity was monitored with
the 6-min walk test.
CASE REPORT
A 36-year-old male presented with a 2-month history of worsen-
ing dyspnoea, weight loss, haemoptysis, oral ulceration, ery-
thema nodosum and superficial thrombophlebitis. He had a
history of anterior uveitis and mild bronchiectasis (recent diag-
nosis on a high-resolution computerized tomography scan of
the chest). Investigations revealed a raised erythrocyte sedimen-
tation rate and C-reactive protein. Anti-neutrophil cytoplasmic
antibodies were negative. A computed tomography pulmonary
angiogram (CTPA) showed bilateral pulmonary arterial thrombi
and aneurysmal dilatation of several pulmonary arteries, with
marked hilar perivascular cuffing. The appearanceswere suggestive
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of pulmonary vasculitis, which was confirmed on a computed
tomography positron emission tomography scan. A diagnosis
of BD was made.
He was commenced on pulsed intravenous (IV) cyclophos-
phamide 1.2 g/pulse and glucocorticoid treatment (initial loading
of 1 g IVmethylprednisolone, followed by 1 mg/kg/day oral pred-
nisolone). At 3 months, he had received 6 pulses of IV cyclophos-
phamide andwas switched to oral azathioprine 2 mg/kg/day. The
prednisolonewasweaned to 15 mg. He also receivedwarfarin (for
6 months in total) for the pulmonary thrombi to maintain Inter-
national Normalized Ratio around 2.5. At 3 months, he was
asymptomatic with normal inflammatory markers. His 6-min
walk test distance had improved from 405 to 510 m (Fig. 1).
Two months later, his respiratory symptoms worsened;
he desaturated on the 6-min walk test for the first time since
cyclophosphamide initiation. His prednisolone was increased
incrementally from 15 mg daily to 40 mg daily, and he was com-
menced on infliximab (5 mg/kg) every 8 weeks (after initial load-
ing) alongsidemethotrexate (increased gradually to 20 mg/week).
This allowed a reduction of prednisolone dose whilst maintain-
ing symptomatic control. Prednisolone was stopped 29 months
after starting infliximab. He felt that hewas approaching his pre-
vious level of fitness; his 6-minwalk test distance (measured at 6-
monthly intervals) mirrored his symptomatic improvement, in-
creasing to 680 m 26 months after initiating infliximab.
A follow-up CTPA (after completing cyclophosphamide ther-
apy) showed resolution of some of the pulmonary artery aneur-
ysms and reduced size of the others, with increased volume of
thrombus of one basal segment pulmonary artery. A further
CTPA (5 months after initiating infliximab) showed resolution
of all previous aneurysms, with ongoing pulmonary arterial oc-
clusion (Fig. 2).
Figure 1: Six-minute walk test distance over time with the lowest oxygen saturations reached on each test. Warfarin was started in May 2012 and cyclophosphamide in
June 2012. Specific time points: (1) September 2012, cyclophosphamide stopped, azathioprine started. Some worsening of symptoms, prednisolone dose increased. (2)
November 2012, worsening of symptoms and desaturation to 76% on 6-min walk test. Prednisolone dose increased further. (3) December 2012, warfarin stopped. (4)
February 2013, infliximab started as patient still short of breath on exertion.
Figure 2: Progression in CTPA appearances: (A) May 2012, pre-treatment; (B) December 2012, 3 months after completion of cyclophosphamide; and (C) July 2013, 5 months
after initiating infliximab. Arrow1: Complete resolution of aneurysm fromMay to December 2012. No recurrence by July 2013. Arrow 2: Reduction in size of aneurysm from
May to December 2012 (maximum arterial diameter 3.2 cm in May and 2.3 cm in December) with increase in volume of thrombus. Reduced volume of thrombus by July
2013.
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DISCUSSION
Pulmonary involvement in BD can take the form of parenchymal
disease (with findings including nodular and cavitating lesions,
ground-glass opacities, pleural effusions and thickening, and
lymphadenopathy) as well as pulmonary vascular involvement
[2]. Pulmonary artery aneurysms (with or without thromboses)
occur most frequently in young males, presenting most com-
monly with haemoptysis around 4 years after disease onset
[1, 2]. The lower lobes of the lungs are most commonly involved,
and there is a strong association with venous involvement else-
where in the body [1, 2]. It carries a poor prognosis due to the risk
of massive (>500 ml) haemoptysis, which is seen in a third of
patients and is commoner in thosewith pulmonary artery aneur-
ysms than those with isolated thrombi [2]. Larger-sized aneur-
ysms (≥3 cm diameter) and higher pulmonary arterial pressures
are associated with a poorer prognosis [2].
European League Against Rheumatism (EULAR) guidelines for
managing BD [5] include using glucocorticoid and cyclophospha-
mide for pulmonary and peripheral arterial aneurysms. Anticoa-
gulants, antiplatelets and antifibrinolytic agents are not
recommended for managing venous thrombi, as clots adhere to
vessel walls and do not generally embolize. These agents also in-
crease the risk of fatal bleeding of any coexisting aneurysms.
However, this remains a controversial issue, and anticoagulants
maystill be used in non-endemic regions in caseswhere the diag-
nosis is initially unclear [6].
In previous published case reports, improvement of pulmon-
ary disease in BD has been achieved using cyclophosphamide,
azathioprine, cyclosporine, mycophenolate, colchicine and
glucocorticoid [1, 2]. Infliximab has been successful in two
cases refractory to cyclophosphamide and two refractory to
azathioprine [2, 7, 8]. Aneurysmal regression may be seen as
early as 15 days after treatment initiation; resolution is seen in
68% of cases [2]. The recurrence rate for pulmonary artery in-
volvement is around 20–25% [1, 2]. Surgical management is re-
served for more severe cases.
In our case, the patient’s symptoms recurred despite treat-
ment with the recommended immunosuppressants. Infliximab
was therefore trialled with good effect. Anti-tumour necrosis fac-
tor alpha (TNFα) agents are in the EULAR recommendations for
managing aspects of BD such as refractory eye, skin, mucosal
or neurological disease; however, they are not suggested for
major vessel disease [5]. The success of infliximab in managing
our patient’s respiratory symptoms in the context of similar
case reports suggests its utility in treating pulmonary vasculitis
in BD that is refractory to conventional therapy.
In a large number of patients with BD, inflammatory mar-
kers may be normal. Recurrent CT scanning is radiation-inten-
sive, and lung function tests are not generally affected by
pulmonary thrombi or aneurysms; therefore, we used the
6-min walk test as a feasible outcome measure. The results cor-
respond well with the symptoms. Although there are outcome
measures like the Birmingham Vasculitis Activity Score (ver-
sion 3) (BVAS(v3)) [9] and Behçet’s Disease Current Activity
Form [10] in use, they fail to address specific concerns like pro-
gression of pulmonary artery vasculitis. We found that the
6-min walk test was a useful adjunct to clinical examination;
it was both easy to perform and responsive to changing phases
of disease activity.
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